Tumor Growth Inhibition by Olaparib in <i>BRCA2</i> Germline-Mutated Patient-Derived Ovarian Cancer Tissue XenograftsUrsula Kortmann, C. Blake Gilks, Hui Xue et al.|Clinical Cancer Research|2010Cited by 70
Relevance of ATM Status in Driving Sensitivity to DNA Damage Response Inhibitors in Patient-Derived Xenograft ModelsAnkur Karmokar, Alan Lau|Cancers|2023Cited by 6